GLP-1 medicines cut fat while preserving muscle function

TL;DR

A March 2026 Cell Reports Medicine study found that GLP-1 medications preferentially burn fat rather than muscle - and that human participants on semaglutide showed no measurable loss of leg strength after 12 weeks. The drugs do reduce fat-free mass, but functional muscle performance appears largely intact.

One of the biggest fears people have about GLP-1 medications is losing muscle. Not the number on the scale going down - the worry that you are hollowing out the wrong tissue. It is a reasonable concern: any significant caloric restriction causes some loss of fat-free mass, and GLP-1 medications produce significant restriction. What this new study published in Cell Reports Medicine in March 2026 adds is a more precise answer - one that distinguishes between losing muscle mass and losing muscle function.

What the study measured - and why that distinction matters

The research team led by Hannah T. Langer ran four preclinical studies using diet-induced obese male mice treated with semaglutide and tirzepatide, alongside a 12-week human pilot trial of 10 adults with obesity and type 2 diabetes on escalating doses of semaglutide up to 1 mg weekly.

The measurement approach was rigorous. For mice: EchoMRI body composition tracking, grip strength testing, treadmill endurance runs, 3D-printed cast immobilisation experiments, and LC-MS/MS proteomics. For humans: B-mode ultrasonography measuring muscle cross-sectional area, maximum voluntary contraction tests, and handgrip dynamometry. They were not just looking at whether muscle tissue was present - they were looking at whether it could still do its job.

The fat vs muscle breakdown

In mice receiving tirzepatide, the overall body weight reduction was 35%. Of that weight loss:

• 73% came from fat mass
• Only 13% came from lean body mass

That is a strongly fat-preferential loss pattern. By comparison, calorie restriction alone typically produces a less favourable ratio - more lean mass lost relative to fat. GLP-1 medications appear to target fat depots more selectively, at least in this animal model.

In the human participants, approximately 70% of weight reduction came from fat loss. That figure aligns well with the mouse data and is consistent with earlier body composition analyses from STEP and SURMOUNT trial sub-studies.

The muscle function finding - the headline result

Here is where the study becomes particularly reassuring. After 12 weeks on semaglutide, human participants showed:

• No statistically significant decline in absolute leg strength
• No statistically significant decline in relative leg strength
• Handgrip strength unchanged from baseline
• Knee extension strength unchanged from baseline

Mice on semaglutide demonstrated endurance performance comparable to lean control animals - animals that had never been obese. That is not a minor finding. It suggests that GLP-1 treatment may actually restore exercise capacity toward a healthier baseline, rather than degrading it.

A separate finding from the mouse proteomics analysis: GLP-1 treatment increased mitochondrial proteins in muscle tissue compared to calorie restriction alone. Mitochondria are the energy factories inside muscle cells - more of them means better metabolic health at the cellular level, even if the muscle is somewhat smaller in absolute terms. The liver showed a much larger proportional mass reduction than skeletal muscle, which also supports the fat-targeting narrative.

How to read this alongside the JCI review's numbers

It is worth holding this study alongside a separate finding from a comprehensive JCI safety review published in the same month. That review, covering data from multiple large clinical trials, found that semaglutide users lose approximately 39% of their total weight as fat-free mass, while tirzepatide users lose approximately 25%.

Those percentages sound alarming until you consider what "fat-free mass" means. It includes more than just muscle - it also includes water, glycogen, organ tissue, and bone mineral content. When you reduce caloric intake significantly, glycogen stores and their associated water (roughly 3-4 grams of water per gram of glycogen) drop substantially. That reduction registers as fat-free mass loss in DEXA scans and MRI, even though no actual muscle protein was broken down.

The Cell Reports Medicine study, by measuring actual strength and endurance performance rather than mass alone, suggests that functional muscle capacity is preserved even as fat-free mass numbers decline on paper. The two findings are not contradictory - they are measuring different things.

What this means if muscle loss is your concern

The honest answer is that GLP-1 medications do reduce some muscle mass - the question is how much, and whether it matters functionally. This study suggests functional impact is minimal over 12 weeks in a small pilot group. Longer-term data across larger populations are still needed, and the authors explicitly flagged that older patients with existing sarcopenia and wasting conditions need their own dedicated research.

If you are on semaglutide or tirzepatide and worried about muscle loss on GLP-1, the most evidence-backed mitigation strategies are:

• Protein intake: current clinical guidance recommends a minimum of 1.2g per kilogram of body weight per day. Some researchers studying GLP-1 users argue for 1.5g/kg. At reduced appetite, hitting these targets takes deliberate effort.
• Resistance exercise: progressive resistance training during GLP-1 treatment consistently preserves lean mass better than cardio alone. Even two sessions per week makes a measurable difference.
• Leucine-rich protein sources: leucine is the branched-chain amino acid most directly responsible for triggering muscle protein synthesis. Eggs, chicken, fish, and Greek yoghurt are practical sources.
• Nutrient support: vitamin D deficiency impairs muscle protein synthesis and is found in 13.6% of GLP-1 users in a 2026 meta-analysis. Vitamin B12 supports nerve-muscle signalling and drops over time on GLP-1 medications due to reduced stomach acid. Both are worth monitoring and supplementing.

The older patient question

The study's authors were clear about one limitation that matters for a significant part of the GLP-1 user population: all preclinical studies used male mice only, and the human pilot had just 10 participants. Older adults - particularly those over 65 who already have reduced muscle mass and slower protein synthesis - were not represented. The muscle preservation story may look different in this group.

A separate JCI review noted that older GLP-1 users (75+) have an 82.6% drug discontinuation rate at 24 months, which partly reflects tolerability issues but may also reflect faster-emerging functional concerns. This is an area where early findings are incomplete, and caution is warranted for patients already at sarcopenia risk.

GLP-1 supplements and the nutrient-muscle connection

The nutritional gaps that GLP-1 medications create are not separate from the muscle question - they are directly connected. Vitamin D supports muscle protein synthesis. Vitamin B12 maintains the nerve signals that drive muscle contraction. Iron carries the oxygen that feeds aerobic muscle metabolism. Protein quantity and quality determine whether your body has the raw material to maintain lean tissue.

GLP-1 users are at documented risk of deficiency in all of these. At GLP-1 Shield, we focus specifically on the nutrient gaps that emerge when your appetite drops significantly - because protecting your muscle long-term requires more than just eating less fat. It requires making sure the smaller amount you eat is nutritionally dense enough to keep the rest of your body functioning.

Frequently asked questions

Do GLP-1 medications cause muscle loss?

GLP-1 medications do reduce fat-free mass, which includes muscle. However, a March 2026 Cell Reports Medicine study found that 70-73% of weight loss came from fat rather than lean tissue, and human participants showed no decline in leg or grip strength after 12 weeks. The drugs appear to preferentially target fat - but ongoing monitoring and adequate protein intake remain important, especially for older adults.

How much protein should I eat on semaglutide or tirzepatide?

Current clinical guidance recommends at least 1.2g of protein per kilogram of body weight per day during GLP-1 treatment. Some researchers advise up to 1.5g/kg. Because appetite is reduced, hitting these targets requires deliberate planning - prioritising protein at every meal rather than letting it come last after carbohydrates and fats.

What vitamins should I take to protect muscle on GLP-1?

Vitamin D and vitamin B12 are the most directly relevant to muscle health. Vitamin D deficiency impairs muscle protein synthesis, and 13.6% of GLP-1 users develop deficiency over time. Vitamin B12 supports the nerve signals that drive muscle contraction and drops as reduced stomach acid limits its absorption. Both are worth monitoring through blood tests and supplementing if levels are low.

Is tirzepatide better than semaglutide for preserving muscle?

Based on available data, tirzepatide users lose a smaller proportion of their weight as fat-free mass (approximately 25%) compared to semaglutide users (approximately 39%), according to a February 2026 JCI review. However, functional muscle strength appears preserved on both drugs according to the Cell Reports Medicine study. Tirzepatide's lower fat-free mass loss may partly reflect its greater overall fat loss rather than superior muscle-sparing properties specifically.